Alzheimer's disease (AD) is an age-related neurodegenerative disorder that is characterized by neurocognitive dysfunction, deposition of amyloid-β (Aβ) plaques, and formation of hyperphosphorylated tau protein. Oxidative stress and neuroinflammation are the main pathological events in AD development. AD is a gender-dependent brain disorder that is predominant in females. Cessation of production of female hormones, such as 17β-estradiol (either due to menopausal or surgical menopause causes), exhibited pro-AD and neurotoxic activities that deteriorate cognitive functions and promote AD development. We investigated the key regulatory role of gender-dependent factors that control the process of AD neuropathogenesis, on the activities of Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome, Nuclear factor erythroid 2-related factor 2 (Nrf2), and Apolipoprotein E (APOE). This review aimed to examine the impact of gender-based differences on incidence rates of AD dementia and to reveal the mechanisms regulating the gender differences in AD. In addition, we highlighted the anti-AD activities of sex hormones and the current application of hormonal replacement therapy and estrogen receptor beta-based therapeutic interventions. Furthermore, we presented the impact of gender differences on metabolism in the brain, insulin resistance, and astrocytic activity.
CanevelliMQuarataFRemiddiF, et al.Sex and sex differences in the treatment of Alzheimer's disease: a systematic review of randomized controlled trials. Pharmacol Res2017; 115: 218–223.
4.
BeamCRKaneshiroCJangJY, et al.Differences between women and men in incidence rates of dementia and Alzheimer’s disease. J Alzheimers Dis2018; 64: 1077–1083.
5.
Castro-AldreteLMoserMVPutignanoG, et al.Sex and gender considerations in Alzheimer’s disease: the women’s brain project contribution. Front Aging Neurosci2023; 15: 1105620.
6.
LynchMA. A case for seeking sex-specific treatments in Alzheimer’s disease. Front Aging Neurosci2024; 16: 1346621.
7.
PlutaR. Gender-dependent modulation of Alzheimer’s disease by brain ischemia. Comment on Lohkamp et al. Sex-specific adaptations in Alzheimer’s disease and ischemic stroke: a longitudinal study in male and female APPswe/PS1dE9 mice. Life (Basel)2025; 15: 1146.
8.
MacLennanAHHendersonVWPaineBJ, et al.Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause2006; 13: 28–36.
EspelandMARappSRShumakerSA, et al.Conjugated equine estrogens and global cognitive function in postmenopausal women: women’s health initiative memory study. J Am Med Assoc2004; 291: 2959–2968.
11.
YueYHuLTianQJ, et al.Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol Sin2007; 28: 1129–1135.
12.
RyanJCarrièreIScaliJ, et al.Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C study. Neurol2009; 73: 1729–1737.
13.
Valen-SendstadAEngedalKStray-PedersenB, et al.Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiat2010; 18: 11–20.
14.
KangJHGrodsteinF. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging2012; 33: 1129–1137.
15.
JacobsEGKroenkeCLinJ, et al.Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use. PloS One2013; 8: e54713.
16.
Bartkowiak-WieczorekJJarosAGajdzińskaA, et al.The dual faces of oestrogen: the impact of exogenous oestrogen on the physiological and pathophysiological functions of tissues and organs. Int J Mol Sci2024; 25: 8167.
17.
JessenFWieseBBachmannC, et al.Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry2010; 67: 414–422.
18.
SherwinBB. Estrogenic effects on memory in women. Ann NY Acad Sci1994; 743: 213–230.
19.
WeiserMJForadoriCDHandaRJ. Estrogen receptor beta in the brain: from form to function. Weiser Brain Res Rev2012; 5: 309–320.
20.
OsterlundMKGustafssonJAKellerE. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J Clin Endocrinol Metab2000; 85: 3840–3846.
21.
VerdileGLawsSMHenleyD, et al.Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease. Mol Psychiatry2014; 19: 69–75.
22.
GourasGKXuHGrossRS. Testosterone reduces neuronal secretion of Alzheimer’s beta-amyloid peptides. Proc Natl Acad Sci U S A2000; 97: 1202–1205.
23.
LeeJWeerasinghe-MudiyanselagePDKimB, et al.Particulate matter exposure and neurodegenerative diseases: a comprehensive update on toxicity and mechanisms. Ecotoxicol Environ Saf2023; 266: 115565.
24.
TripathiSKharkwalGMishraR, et al.Nuclear factor erythroid 2-related factor 2 (Nrf2) signaling in heavy metals-induced oxidative stress. Heliyon2024; 10: e37545.
AnsarianMAFatahichegeniMRenJ, et al.Sex and gender in myeloid and lymphoblastic leukemias and multiple myeloma: from molecular mechanisms to clinical outcomes. Curr Oncol2025; 32: 204.
27.
vom SteegLGKleinSL. SeXX matters in infectious disease pathogenesis. PLoS Pathog2016; 12: e1005374.
28.
WilliamsJSFattoriMRHoneyborneIR, et al.Considering hormones as sex-and gender-related factors in biomedical research: challenging false dichotomies and embracing complexity. Horm Behave2023; 156: 105442.
29.
ShenLSongLLiH, et al.Association between earlier age at natural menopause and risk of diabetes in middle-aged and older Chinese women: the Dongfeng-Tongji cohort study. Diabetes Metab2017; 43: 345–350.
30.
CiarambinoTCrispinoPLetoG, et al.Influence of gender in diabetes mellitus and its complication. Int J Mol Sci2022; 23: 8850.
31.
BiancoAAntonacciYLiguoriM. Sex and gender differences in neurodegenerative diseases: challenges for therapeutic opportunities. Int J Mol Sci2023; 24: 6354.
32.
PetersSAHuxleyRRWoodwardM. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia2014; 57: 1542–1551.
33.
WagnerADOertelt-PrigioneSAdjeiA, et al.Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol2019; 30: 1914–1924.
34.
KimYRJungYKangI, et al.Understanding sex differences in autoimmune diseases: immunologic mechanisms. Int J Mol Sci2025; 26: 7101.
35.
ForsythKSJiwrajkaNLovellCD, et al.The conneXion between sex and immune responses. Nat Rev Immunol2024; 24: 487–502.
36.
ShepherdRCheungASPangK, et al.Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol2021; 11: 604000.
37.
MielkeMMVemuriPRoccaWA. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clin Epidemiol2014; 6: 37–48.
38.
BradyBZhengLKootarS, et al.Sex and gender differences in risk scores for dementia and Alzheimer's disease among cisgender, transgender, and non-binary adults. Alzheimers Dement2024; 20: 5–15.
39.
FerrettiMTMartinkovaJBiskupE. Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice: position paper of the dementia and cognitive disorders panel of the European academy of neurology. Eur J Neurol2020; 27: 928–943.
40.
NicolettiABaschiRCiceroCE. Sex and gender differences in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis: a narrative review. Mech Ageing Dev2023; 212: 111821.
41.
BaldacciFListaSMancaML. Age and sex impact plasma NFL and t-tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimers Res Ther2020; 12: 147.
42.
GustavssonANortonNFastT, et al.Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement2023; 19: 658–670.
43.
SundermannEEBiegonARubinLH, et al.Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurol2016; 86: 1368–1376.
44.
ArdekaniBAConvitABachmanAH. Analysis of the MIRIAD data shows sex differences in hippocampal atrophy progression. J Alzheimers Dis2016; 50: 847–857.
45.
LeeJChoHJeonS, et al.Sex-related reserve hypothesis in Alzheimer’s disease: changes in cortical thickness with a five-year longitudinal follow-up. J Alzheimers Dis2018; 65: 641–649.
46.
EmraniSSundermannEE. Sex/gender differences in the clinical trajectory of Alzheimer’s disease: insights into diagnosis and cognitive reserve. Front Neuroendocrinol2025; 77: 101184.
47.
CaldwellJZBergJLCummingsJL, et al.Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimers Res Ther2017; 9: 72.
48.
CaldwellJZCummingsJLBanksSJ, et al.Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimers Res Ther2019; 11: 109.
49.
NelsonLHPeketiPLenzKM. Microglia regulate cell genesis in a sex-dependent manner in the neonatal hippocampus. Neurosci2021; 453: 237–255.
50.
KimYYangGRPradhanK, et al.Brain-wide maps reveal stereotyped cell-type-based cortical architecture and subcortical sexual dimorphism in brief. Cell2017; 171: 456–469.
51.
GuebelDV. Human hippocampal astrocytes: computational dissection of their transcriptome, sexual differences and exosomes across ageing and mild-cognitive impairment. Eur J Neurosci2023; 58: 2677–2707.
52.
YasudaKMakiTKinoshitaH, et al.Sex-specific differences in transcriptomic profiles and cellular characteristics of oligodendrocyte precursor cells. Stem Cell Res2020; 46: 101866.
53.
WingoAPLiuYGerasimovES, et al.Sex differences in brain protein expression and disease. Nat Med2023; 29: 2224–2232.
54.
BaumgartnerNEBiraudMCLucasEK. Sex differences in socioemotional behavior and changes in ventral hippocampal transcription across aging in C57Bl/6J mice. Neurobiol Aging2023; 130: 141–153.
55.
RosarioERCarrollJCPikeCJ. Evaluation of the effects of testosterone and luteinizing hormone on regulation of β-amyloid in male 3xTg-AD mice. Brain Res2012; 1466: 137–145.
56.
SchelbaumELoughlinLJettS, et al.Association of reproductive history with brain MRI biomarkers of dementia risk in midlife. Neurol2021; 97: e2328–e2339.
57.
BrintonRDYaoJYinF, et al.Perimenopause as a neurological transition state. Nat Rev Endocrinol2015; 11: 393–405.
58.
CrayLWoodsNFMitchellES. Symptom clusters during the late menopausal transition stage: observations from the Seattle midlife women's health study. Menopause2010; 17: 972–977.
59.
BreezeBConnellEWilemanT, et al.Menopause and Alzheimer’s disease susceptibility: exploring the potential mechanisms. Brain Res2024; 1844: 149170.
60.
ScheyerORahmanAHristovH, et al.Female sex and Alzheimer’s risk: the menopause connection. J Prev Alzheimers Dis2018; 5: 225–230.
61.
YaoJBrintonRD. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer’s disease. Adv Pharmacol2012; 64: 327–371.
62.
LejriIGrimmAEckertA. Mitochondria, estrogen and female brain aging. Front Aging Neurosci2018; 10: 124.
63.
GannonOJNaikJSRiccioD, et al.Menopause causes metabolic and cognitive impairments in a chronic cerebral hypoperfusion model of vascular contributions to cognitive impairment and dementia. Biol Sex Differ2023; 14: 34.
64.
OlajideOJBurrowesAABda SilvaIF, et al.Reduced 17β-estradiol following ovariectomy induces mitochondrial dysfunction and degradation of synaptic proteins in the entorhinal cortex. Neuroscience2025; 565: 479–486.
65.
MosconiLBertiVQuinnC, et al.Sex differences in Alzheimer risk: brain imaging of endocrine vs chronologic aging. Neurol2017; 89: 1382–1390.
66.
BoveRSecorEChibnikLB, et al.Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurol2014; 82: 222–229.
67.
ZhaoLYaoJMaoZ, et al.17beta-Estradiol Regulates insulin-degrading enzyme expression via an ERbeta/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Neurobiol Aging2011; 32: 1949–1963.
68.
DubalDB. Sex difference in Alzheimer's disease: an updated, balanced and emerging perspective on differing vulnerabilities. Handb Clin Neurol2020; 175: 261–273.
69.
SinghMSuC. Progesterone and neuroprotection. Horm Behav2013; 63: 284–290.
70.
XiongJKangSSWangZ, et al.FSH Blockade improves cognition in mice with Alzheimer's disease. Nature2022; 603: 470–476.
71.
Valencia-OlveraACMaldonado WengJChristensenA, et al.Role of estrogen in women's Alzheimer's disease risk as modified by APOE. J Neuroendocrinol2023; 35: e13209.
72.
TaxierLRGrossKSFrickKM. Oestradiol as a neuromodulator of learning and memory. Nat Rev Neurosci2020; 21: 535–550.
73.
IshikawaAMatsushitaHShimizuS, et al.Impact of menopause and the menstrual cycle on oxidative stress in Japanese women. J Clin Med2023; 12: 829.
74.
LiangKYangLYinC, et al.Estrogen stimulates degradation of β-amyloid peptide by up-regulating neprilysin. J Biol Chem2010; 285: 935–942.
75.
HuYTChenXLZhangYN, et al.Sex differences in hippocampal β-amyloid accumulation in the triple-transgenic mouse model of Alzheimer’s disease and the potential role of local estrogens. Front Neurosci2023; 17: 1117584.
76.
GaignardPSavourouxSLiereP, et al.Effect of sex differences on brain mitochondrial function and its suppression by ovariectomy and in aged mice. Endocrinol2015; 156: 2893–2904.
77.
GaignardPLierePThérondP, et al.Role of sex hormones on brain mitochondrial function, with special reference to aging and neurodegenerative diseases. Frontiers Aging Neurosci2017; 9: 406.
78.
MeemaSBunkerMLMeemaHE. Preventive effect of estrogen on postmenopausal bone loss: a follow-up study. Archiv Intern Med1975; 135: 1436–1440.
79.
YusufSAnandS. Hormone replacement therapy: a time for pause. CMAJ2002; 167: 357–359.
80.
DubalDBKashonMLPettigrewLC, et al.Estradiol protects against ischemic injury. J Cereb Blood Flow Metab1998; 18: 1253–1258.
81.
Guevara-GuzmánRArriagaVKendrickKM, et al.Estradiol prevents ozone-induced increases in brain lipid peroxidation and impaired social recognition memory in female rats. Neurosci2009; 159: 940–950.
82.
CaceresLGUranSLZorrilla ZubileteMA, et al.An early treatment with 17-β-estradiol is neuroprotective against the long-term effects of neonatal ionizing radiation exposure. J Neurochem2011; 118: 626–635.
83.
RamezaniAGoudarziILashkarboloukiT, et al.Neuroprotective effects of the 17β-estradiol against ethanol-induced neurotoxicity and oxidative stress in the developing male rat cerebellum: biochemical, histological and behavioral changes. Pharmacol Biochem Behav2011; 100: 144–151.
84.
BarakaAMKorishAASolimanGA, et al.The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease. Life Sci2011; 88: 879–885.
85.
RaoAKDietrichAKZieglerYS, et al.17β-Estradiol-mediated Increase in Cu/Zn superoxide dismutase expression in the brain: a mechanism to protect neurons from ischemia. J Steroid Biochem Mol Biol2011; 127: 382–389.
86.
ReedEGKeller-NorrellPR. Minding the gap: exploring neuroinflammatory and microglial sex differences in Alzheimer’s disease. Int J Mol Sci2023; 24: 17377.
87.
ZhaoLWoodySKChhibberA. Estrogen receptor β in Alzheimer’s disease: from mechanisms to therapeutics. Ageing Res Rev2015; 24: 178–190.
88.
MurerMGYanQRaisman-VozariR. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol2001; 63: 71–124.
89.
SohrabjiFMirandaRCToran-AllerandCD. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci U S A1995; 92: 11110–11114.
90.
AguirreCCBaudryM. Progesterone reverses 17β-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. European J Neurosci2009; 29: 447–454.
91.
AguirreCJayaramanAPikeC, et al.Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-β. J Neurochem2010; 115: 1277–1287.
HaraYWatersEMMcEwenBS, et al.Estrogen effects on cognitive and synaptic health over the lifecourse. Physiol Rev2015; 95: 785–807.
94.
RettbergJRYaoJBrintonRD. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol2014; 35: 8–30.
95.
JettSMalviyaNSchelbaumE, et al. Endogenous and exogenous estrogen exposures: how women’s reproductive health can drive brain aging and inform Alzheimer’s prevention. Front Aging Neurosci2022; 14: 831807.
96.
Wood AlexanderMHonerWGSalonerR, et al. The interplay between age at menopause and synaptic integrity on Alzheimer’s disease risk in women. Sci Adv2025; 11: eadt0757.
97.
KawasCResnickSMorrisonA, et al.A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore longitudinal study of aging. Neurol1997; 48: 1517–1521.
98.
KhanISaeedKJoMG, et al. 17-β Estradiol rescued immature rat brain against glutamate-induced oxidative stress and neurodegeneration via regulating Nrf2/HO-1 and MAP-kinase signaling pathway. Antioxidants (Basel)2021; 10: 892.
99.
RissmanEFHeckALLeonardJE, et al.Disruption of estrogen receptor β gene impairs spatial learning in female mice. Proc Natl Acad Sci U S A2002; 99: 3996–4001.
100.
DayMSungALogueS, et al.Beta estrogen receptor knockout (BERKO) mice present attenuated hippocampal CA1 long-term potentiation and related memory deficits in contextual fear conditioning. Behav Brain Res2005; 164: 128–131.
101.
GassMLStuenkelCAUtianWH, et al.Use of compounded hormone therapy in the United States: report of the north American menopause society survey. Menopause2015; 22: 1276–1285.
102.
GeorgeSPetitGHGourasGK. Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer’s disease. ACS Chem Neurosci2013; 4: 1537–1548.
103.
TakayamaKIFujiwaraKInoueS. Amyloid precursor protein, an androgen-regulated gene, is targeted by RNA-binding protein PSF/SFPQ in neuronal cells. Genes Cells2019; 24: 719–730.
104.
LeiYRenyuanZ. Effects of androgens on the amyloid-β protein in Alzheimer's disease. Endocrinol2018; 159: 3885–3894.
105.
ShimMBangWJOhCY, et al.Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?Prostate Int2022; 10: 68–74.
106.
CarrollJCRosarioERKreimerS, et al.Sex differences in b-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res2010; 1366: 233–245.
107.
CarusoDBarronAMBrownMA, et al.Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol Aging2013; 34: 1080–1089.
108.
WahjoepramonoEJWijayaLKTaddeiK, et al.Distinct effects of testosterone on plasma and cerebrospinal fluid amyloid-beta levels. J Alzheimers Dis2008; 15: 129–137.
109.
HouYBaoXQWeiHL, et al.Long-term deprivation of gonadal hormone accelerates brain aging in mice. Neurol Res2013; 33: 43–49.
110.
SivanandamTMThakurMK. Amyloid precursor protein (APP) mRNA level is higher in the old mouse cerebral cortex and is regulated by sex steroids. J Molec Neurosci2010; 43: 235–240.
111.
DrummondESMartinsRNHandelsmanDJ, et al.Altered expression of Alzheimer’s disease–related proteins in male hypogonadal mice. Endocrinol2012; 153: 2789–2799.
112.
EblingFJNwagwuMOBainesH, et al.The hypogonadal (hpg) mouse as a model to investigate the estrogenic regulation of spermatogenesis. Hum Fertil2006; 9: 127–135.
113.
McAllisterCLongJBowersA, et al.Genetic targeting aromatase in male amyloid precursor protein transgenic mice downregulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment. J Neurosci2010; 30: 7326–7334.
114.
RosarioERCarrollJPikeCJ. Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res2010; 1359: 281–290.
115.
RamsdenMNyborgACMurphyMP, et al.Androgens modulate beta-amyloid levels in male rat brain. J Neurochem2004; 87: 1052–1055.
116.
AsihPRWahjoepramonoEJAniwiyantiV, et al.Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety. CNS Neurol Disord-Drug Targets2015; 14: 576–586.
117.
YanXSYangZJJiaJX, et al.Protective mechanism of testosterone on cognitive impairment in a rat model of Alzheimer's disease. Neural Regen Res2019; 14: 649–657.
118.
MohamadNVIma-NirwanaSChinKY. A review on the effects of testosterone supplementation in hypogonadal men with cognitive impairment. Curr Drug Targets2018; 19: 898–906.
119.
OksanenMLehtonenSJaronenM, et al.Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Cell Mol Life Sci2019; 76: 2739–2760.
120.
Fuente-MartinEGarcia-CaceresCMorselliE, et al.Estrogen, astrocytes and the neuroendocrine control of metabolism. Rev Endocr Metab Disord2013; 14: 331–338.
121.
MorkenTSBrekkeEHåbergA, et al.Altered astrocyte–neuronal interactions after hypoxia-ischemia in the neonatal brain in female and male rats. Stroke2014; 45: 2777–2785.
122.
VerkhratskyANedergaardM. Physiology of astroglia. Physiol Rev2018; 98: 239–389.
123.
Pacheco-SánchezBTovarRBen RabaaM, et al.Sex-dependent altered expression of cannabinoid signaling in hippocampal astrocytes of the triple transgenic mouse model of Alzheimer’s disease: implications for controlling astroglial activity. Int J Mol Sci2023; 24: 12598.
124.
EdwardsHMWallaceCEGardinerWD, et al.Sex-dependent effects of acute stress on amyloid-β in male and female mice. Brain2023; 146: 2268–2274.
125.
Ibrahim FouadGMabroukMEl-SayedSA, et al. Berberine-loaded iron oxide nanoparticles alleviate cuprizone-induced astrocytic reactivity in a rat model of multiple sclerosis. Biometals2025; 38: 203–229.
126.
EscartinCGaleaELakatosA, et al.Reactive astrocyte nomenclature, definitions, and future directions. Nature Neurosci2021; 24: 312–325.
127.
LabonteJPettwayECSugarmanM, et al.Sex differences on tau, astrocytic and neurodegeneration plasma biomarkers. Alzheimers Dement2023; 19: e071807.
128.
SpenceRDHambyMEUmedaE, et al.Neuroprotection mediated through estrogen receptor-α in astrocytes. Proc Natl Acad Sci U S A2011; 108: 8867–8872.
129.
ItohNItohYMeyerCE, et al.Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female mice. Nat Commun2023; 14: 6044.
130.
WangJSareddyGRLuY, et al.Astrocyte-derived estrogen regulates reactive astrogliosis and is neuroprotective following ischemic brain injury. J Neurosci2020; 40: 9751–9771.
131.
YoonSSJoSA. Mechanisms of amyloid-β peptide clearance: potential therapeutic targets for Alzheimer’s disease. Biomol Ther2012; 20: 245–255.
132.
ŻukowskaJMossSJSubramanianV, et al.Molecular basis of selective amyloid-β degrading enzymes in Alzheimer’s disease. FEBS J2024; 291: 2999–3029.
133.
UllahRLeeEJ. Advances in amyloid-β clearance in the brain and periphery: implications for neurodegenerative diseases. Exp Neurobiol2023; 32: 216–246.
134.
HoeHSCooperMJBurnsMP, et al.The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci2007; 27: 10895–10905.
135.
TrentiniAManfrinatoMCCastellazziM, et al.Sex-related differences of matrix metalloproteinases (MMPs): new perspectives for these biomarkers in cardiovascular and neurological diseases. J Pers Med2022; 12: 1196.
136.
RosenbergGA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol2009; 8: 205–216.
137.
AksnesMEdwinTHSaltvedtI, et al.Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease. Biol Sex Differ2023; 14: 35.
138.
Hernandez-GuillamonMMawhirtSBlaisS, et al.Sequential amyloid-β degradation by the matrix metalloproteases MMP-2 and MMP-9. J Biol Chem2015; 290: 15078–15091.
139.
TanMSTanLJiangT, et al.Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Dis2014; 5: e1382.
140.
FannDYLeeSYManzaneroS, et al.Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis2013; 4: e790.
141.
SaresellaMLa RosaFPianconeF, et al.The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol Neurodegener2016; 11: 23.
142.
ZhangJPeiLZangD, et al.Sex differences of NLRP1 inflammasome in mouse model of Alzheimer's disease. Front Aging Neurosci2020; 12: 512097.
143.
YapJKYPickardBSChanEWL, et al.The role of neuronal NLRP1 inflammasome in Alzheimer's disease: bringing neurons into the neuroinflammation game. Mol Neurobiol2019; 56: 7741–7753.
144.
SadleirKREimerWAColeSL, et al.Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener2015; 10: 1.
145.
BundyJLViedCBadgerC, et al.Sex-biased hippocampal pathology in the 5XFAD mouse model of Alzheimer’s disease: a multi-omic analysis. J Comp Neurol2019; 527: 462–475.
146.
De Castro-JorgeLAde CarvalhoRVKleinTM, et al.The NLRP3 inflammasome is involved with the pathogenesis of Mayaro virus. PLoS Pathog2019; 15: e1007934.
147.
KimBRKimBJKookYH, et al.Mycobacterium abscessus infection leads to enhanced production of type 1 interferon and NLRP3 inflammasome activation in murine macrophages via mitochondrial oxidative stress. PLoS Pathog2020; 16: e1008294.
148.
DongWPengQLiuZ, et al.Estrogen plays an important role by influencing the NLRP3 inflammasome. Biomed Pharmacother2023; 167: 115554.
149.
FrikerLLScheiblichHHochheiserIV, et al.β-amyloid clustering around ASC fibrils boosts its toxicity in microglia. Cell Rep2020; 30: 3743–3754.
150.
HabibPHarmsJZendedelA, et al.Gonadal hormones E2 and P mitigate cerebral ischemia-induced upregulation of the AIM2 and NLRC4 inflammasomes in rats. Int J Mol Sci2020; 21: 4795.
151.
SlowikALammerdingLHoffmannS, et al.Brain inflammasomes in stroke and depressive disorders: regulation by oestrogen. J Neuroendocrinol2018; 30: e12482.
152.
Gomez LopezM, Dominguez LopezA, Abarca RojanoE, et al. 17 β-Estradiol transcriptionally modulates Nlrp1 and Nlrp3 inflammasomes in gonadectomized rats with inflammation. Immunopharmacol Immunotoxicol2015; 37: 343–350.
153.
NerattiniMJettSAndyC, et al.Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer’s disease and dementia. Front Aging Neurosci2023; 15: 1260427.
154.
ChakrabartiMDasASamantarayS, et al.Molecular mechanisms of estrogen for neuroprotection in spinal cord injury and traumatic brain injury. Rev Neurosci2016; 27: 271–281.
155.
XuYShengHBaoQ, et al.NLRP3 Inflammasome activation mediates estrogen deficiency-induced depression-and anxiety-like behavior and hippocampal inflammation in mice. Brain Behav Immun2016; 56: 175–186.
156.
LliberosCLiewSHMansellA, et al.The inflammasome contributes to depletion of the ovarian reserve during aging in mice. Front Cell Dev Biol2021; 8: 628473.
157.
LliberosCLiewSHZareieP, et al.Evaluation of inflammation and follicle depletion during ovarian ageing in mice. Scie Rep2021; 11: 278.
158.
YeJSChenLLuYY, et al.Honokiol-mediated mitophagy ameliorates postoperative cognitive impairment induced by surgery/sevoflurane via inhibiting the activation of NLRP3 inflammasome in the hippocampus. Oxid Med Cell Longev2019; 2019: 8639618.
159.
HendersonVWBuckwalterJG. Cognitive deficits of men and women with Alzheimer's disease. Neurology1994; 44: 90–96.
160.
FeketeCVastaghCDénesÁ, et al.Chronic amyloid β oligomer infusion evokes sustained inflammation and microglial changes in the rat hippocampus via NLRP3. Neurosci2019; 405: 35–46.
161.
SaadMAAl-ShorbagyMYArabHH. Targeting the TLR4/NF-κΒ axis and NLRP1/3 inflammasomes by rosuvastatin: a role in impeding ovariectomy-induced cognitive decline neuropathology in rats. Mol Neurobiol2022; 59: 4562–4577.
162.
Rojo de la VegaMDodsonMGrossC, et al. Role of Nrf2 and autophagy in acute lung injury. Curr Pharmacol Rep2016; 2: 91–101.
163.
MaQ. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol2013; 53: 401–426.
164.
ZhaoCGilletteDDLiX, et al.Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J Biol Chem2014; 289: 17020–17029.
165.
TangZHuBZangF, et al.Nrf2 drives oxidative stress-induced autophagy in nucleus pulposus cells via a Keap1/Nrf2/p62 feedback loop to protect intervertebral disc from degeneration. Cell Death Dis2019; 10: 510.
166.
Ibrahim FouadG. Sulforaphane, an Nrf-2 agonist, modulates oxidative stress and inflammation in a rat model of cuprizone-induced cardiotoxicity and hepatotoxicity. Cardiovasc Toxicol2023; 23: 46–60.
167.
GaoBDoanAHybertsonBM. The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clin Pharmacol2014; 3: 19–34.
MaierNKLepplaSHMoayeriM. The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes. J Immunol2015; 194: 2776–2785.
172.
GreaneyAJMaierNKLepplaSH, et al.Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J Leukoc Biol2016; 99: 189–199.
173.
GarstkiewiczMStrittmatterGEGrossiS, et al.Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression. Eur J Immunol2017; 47: 806–817.
174.
SuzukiTYamamotoM. Molecular basis of the Keap1–Nrf2 system. Free Radic Biol Med2015; 88: 93–100.
175.
LeeSChoiSYChooYY, et al.Sappanone A exhibits anti-inflammatory effects via modulation of Nrf2 and NF-κB. Int Immunopharmacol2015; 28: 328–336.
176.
RojoAJPajaresMGarcía-YagüeAJ, et al.Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biol2018; 18: 173–180.
177.
DaviesDAAdlimoghaddamAAlbensiBC. Role of Nrf2 in synaptic plasticity and memory in Alzheimer’s disease. Cells2021; 10: 1884.
178.
ZhangYChenKSloanSA, et al.An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci2014; 34: 11929–11947.
179.
BrancaCFerreiraENguyenTV, et al.Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer’s disease. Hum Mol Genet2017; 26: 4823–4835.
180.
SoniPSharmaSMPieperAA, et al.Nrf2/Bach1 signaling axis: a promising multifaceted therapeutic strategy for Alzheimer's disease. Neurotherapeutics2025; 22: e00586.
181.
JiwajiZTiwariSSAvilés-ReyesRX, et al.Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nat Commun2022; 13: 135.
182.
GeorgeMTharakanMCulbersonJ, et al.Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases. Ageing Res Rev2022; 82: 101756.
183.
ChuCTUrunoAKatsuokaF, et al.Role of NRF2 in pathogenesis of Alzheimer’s disease. Antioxidants (Basel)2024; 13: 1529.
184.
PomattoLCSunPYYuK, et al.Limitations to adaptive homeostasis in an hyperoxia-induced model of accelerated ageing. Redox Biol2019; 24: 101194.
QuZSunJZhangW, et al.Transcription factor NRF2 as a promising therapeutic target for Alzheimer’s disease. Free Radic Biol Med2020; 159: 87–102.
187.
IshiiTWarabiE. Mechanism of rapid nuclear factor-E2-related factor 2 (Nrf2) activation via membrane-associated estrogen receptors: roles of NADPH oxidase 1, neutral sphingomyelinase 2 and epidermal growth factor receptor (EGFR). Antioxidants2019; 8: 69.
188.
SprouseJSampathCGangulaPR. Role of sex hormones and their receptors on gastric Nrf2 and neuronal nitric oxide synthase function in an experimental hyperglycemia model. BMC Gastroenterol2020; 20: 313.
189.
DemetriusLAEckertAGrimmA. Sex differences in Alzheimer’s disease: metabolic reprogramming and therapeutic intervention. Trends Endocrinol Metab2021; 32: 963–979.
190.
JullienneASzuJIQuanR, et al.Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer’s disease. Front Aging Neurosci2023; 15: 1220036.
191.
RobisonLSGannonOJSalineroAE, et al.Sex differences in metabolic phenotype and hypothalamic inflammation in the 3xTg-AD mouse model of Alzheimer’s disease. Biol Sex Differ2023; 4: 51.
DalyCMSaxenaJSinghJ, et al.Sex differences in response to a high fat, high sucrose diet in both the gut microbiome and hypothalamic astrocytes and microglia. Nutr Neurosci2022; 25: 321.
194.
López-GamberoAJPacheco-SánchezBRosell-ValleC, et al.Dietary administration of D-chiro-inositol attenuates sex-specific metabolic imbalances in the 5xFAD mouse model of Alzheimer’s disease. Biomed Pharmacother2022; 150: 112994.
195.
ShippyDCUllandTK. Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation. Sci Rep2023; 13: 14800.
196.
TramuntBSmatiSGrandgeorgeN, et al.Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia2020; 63: 453–461.
197.
AnagnostisPChristouKArtzouchaltziAM, et al.Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol2019; 180: 41–50.
198.
ChaudharyRLikidlilidAPeerapatditT, et al.Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol2012; 11: 36.
199.
YinYWQiaoLSunQQ, et al.Influence of apolipoprotein E gene polymorphism on development of type 2 diabetes mellitus in Chinese Han population: a meta-analysis of 29 studies. Metabolism2014; 63: 532–541.
200.
MontemariALMancoMFiocchiAG, et al.An inflammatory signature of glucose impairment in cystic fibrosis. J Inflammation Res2022; 15: 5677–5685.
201.
ZhaoLHuHZhangL, et al.Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions. Med Comm2024; 5: e516.
202.
LiMChiXWangY, et al.Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther2022; 7: 216.
203.
ChenDWShiJKLiY, et al.Association between ApoE polymorphism and type 2 diabetes: a meta-analysis of 59 studies. Biomed Environ Sci2019; 32: 823–838.
204.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet2020; 396: 413–446.
205.
NordestgaardLTChristoffersenMFrikke-SchmidtR. Shared risk factors between dementia and atherosclerotic cardiovascular disease. Int J Mol Sci2022; 23: 9777.
206.
LiuCCKanekiyoTXuH, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
207.
WardACreanSMercaldiCJ, et al.Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiol2012; 38: 1–17.
208.
HeLNReckerRRDengHW, et al.A polymorphism of apolipoprotein E (APOE) gene is associated with age at natural menopause in Caucasian females. Maturitas2009; 62: 37–41.
209.
GamacheJYunYChiba-FalekO. Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders. Dis Model Mech2020; 13: dmm045211.
210.
ZhaoLMorganTEMaoZ, et al.Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles. PloS One2012; 7: e31267.
WugalterKASchroederRAThurstonRC, et al.Associations of endogenous estrogens, plasma Alzheimer’s disease biomarkers, and APOE4 carrier status on regional brain volumes in postmenopausal women. Front Aging Neurosci2024; 16: 1426070.
213.
KunzlerJYoumansKLYuC, et al.APOE Modulates the effect of estrogen therapy on aβ accumulation EFAD-tg mice. Neurosci Lett2014; 560: 131–136.
214.
ThomasRZuchowskaPMorrisAW, et al.Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. Acta Neuropathol Commun2016; 4: 111.
215.
YoumansKLTaiLMNwabuisi-HeathE, et al.APOE4-specific Changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem2012; 287: 41774–41786.
216.
PontifexMGMartinsenASalehRNM, et al.APOE4 Genotype exacerbates the impact of menopause on cognition and synaptic plasticity in APOE-TR mice. FASEB J2021; 35: e21583.
217.
ChangYLFennema-NotestineCHollandD, et al.APOE Interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. Alzheimers Dement2014; 10: 336–348.
218.
AliNSohailRJafferSR, et al.The role of estrogen therapy as a protective factor for Alzheimer’s disease and dementia in postmenopausal women: a comprehensive review of the literature. Cureus2023; 15: e43053.
219.
EliyahuEKatzMGVincekA, et al.Effects of hormone replacement therapy on women's lung health and disease. Pulm Ther2023; 9: 461–477.
220.
DubalDBWisePM. Estrogen and neuroprotection: from clinical observations to molecular mechanisms. Dialogues Clin Neurosci2002; 4: 149–161.
221.
HodisHNMackWJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing. Cancer J2022; 28: 208–223.
222.
SayfullaevaJMcLoughlinJKwakowskyA. Hormone replacement therapy and Alzheimer’s disease: current state of knowledge and implications for clinical use. J Alzheimers Dis2024; 101: S235–S261.
223.
WebberLDaviesMAndersoR, et al.European society for human reproduction and embryology (ESHRE) guideline group on POI. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod2016; 31: 926–937.
